secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0000950170-23-015003
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics secures $26.25M secured development line of credit at 7% fixed rate
--------------------------------------------------------------------------------

- Agreement with Prime Capital Ventures, LLC for secured development line of credit up to $26.25M.
- Note bears 7% fixed interest per annum, due monthly; principal and accrued interest due April 20, 2028.
- $5.25M interest reserve and a $1.25M non-refundable fee payable from initial advance.
- Initial advance subject to permits and compliance; lender gets first priority lien on new Miramar facility.
- Covenants restrict liens, indebtedness, investments, mergers, and charter/bylaw amendments adverse to lender.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017023015003/0000950170-23-015003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017023015003/hcwb-20230421.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-015003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer